Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
26 results
D1.264 - Assessment by general practitioners of a therapeutic patient education guide for allergic patients
D1.262 - Clinical significance of a basophil activation test for Japanese beekeepers naturally sensitized to honey bee venom
D1.265 - Component-Resolved Diagnosis and Clinical Profiles of Anisakis Allergy in Japan
D1.266 - Investigation of anaphylaxis in mastocytosis mouse models
D1.267 - Recurrence of perioperative anaphylaxis: analysis of a multicenter cohort
D1.268 - The endothelial glycocalyx as a therapeutic target in anaphylaxis
D1.269 - Deciphering cardiovascular profiles in sera and extracellular vesicles from anaphylactic patients. Impact in endothelial cells
D1.270 - Anaphylaxis and Adrenaline: Knowledge gaps with critical consequences
D1.271 - Bovine gelatine-induced anaphylaxis brought on by eating beef, sweets containing gelatin, and medications
D1.272 - Efficacy and Safety of Omalizumab in Treating Severe Allergic Reactions with Urticaria as the Initial Symptom
D1.273 - Anaphylactic Reaction Following Sulphur Hexafluoride Administration
D3.265 - Biphasic anaphylaxis secondary to polyethylene glycol in a pediatric patient: a case report
D3.268 - Chronic Allergen Exposure Induces Accumulation of IgE Plasma Cells in the Lung, Leading to Local IgE Antibody Production
D3.269 - Drug-Induced Anaphylaxis in Children: A Comparative Analysis of Inpatient vs. Outpatient Settings
D3.270 - A novel workflow for cell metabolomics: impact of anaphylaxis in a human endothelial system
D3.272 - Safety and Efficacy of Vancomycin and Other Antimicrobial Drug Desensitization in Pediatric Patients
D3.273 - Assessing Anaphylaxis in COVID-19 vaccines: Application of amended Brighton Collaboration Criteria
D3.274 - Succesful Omalizumab Desensitization in Two Children with Severe Allergic Asthma and Cronic Spontaneous Urticaria
D3.275 - Anaphylaxis caused by polyhexanide
D3.276 - Acalabrutinib as premedication in platinum agents desensitization protocols: a case series supporting its role in enhancing tolerance with a repeatible efficacity
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download